Skip to content
lifestyle.independent.mk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Erasca, Inc.
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
August 24, 2026
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
August 11, 2026
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2026
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
August 10, 2026
Erasca to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Erasca Reports First Quarter 2026 Business Updates and Financial Results
May 23, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
May 22, 2026
Erasca to Present at the Bank of America Securities Health Care Conference
May 22, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
May 20, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
May 20, 2026
1
2
Next Page
→